Is Medicamen Organ. overvalued or undervalued?

As of 17 November 2025, Medicamen Organ. has moved from a fair to an attractive valuation grade. The company appears to be undervalued, particularly when considering its key ratios: a PE ratio of 9.84, an EV to EBITDA of 7.39, and a ROCE of 12.71%. In comparison to its peers, Medicamen's valuation is significantly lower than Sun Pharma's PE ratio of 36.69 and Divi's Lab's PE ratio of 69.78, which are categorized as very expensive.
Despite the attractive valuation, Medicamen has faced substantial stock declines, with a year-to-date return of -48.98%, contrasting sharply with the Sensex's positive return of 10.02%. This divergence suggests that the market may not fully recognize the company's potential, reinforcing the conclusion that Medicamen Organ. is undervalued in the current market environment.